Moreover, our preliminary studies indicate that DCLK1 knockdown sensitizes RCC cells to receptor tyrosine kinase inhibitor sunitinib (Fig S3E), which may be beneficial in early treatment or extend sunitinib's efficacy after resistance has developed. Here, DCLK1 is linked to renal cell carcinoma.